News Daily News ACE Inhibitors/ARBs Safe, Possibly Protective in Hypertensive COVID-19 Patients Caitlin E. Cox April 24, 2020
News Daily News COVID-19 Should Not Guide Use of ACE Inhibitors/ARBs, Heart Societies Say Todd Neale March 17, 2020
News Conference News HFSA 2019 New PROVE-HF Data May Reassure Clinicians of Sacubitril/Valsartan Benefit in HFrEF L.A. McKeown September 18, 2019
News Features ESC Heart Failure 2019 At the ESC Heart Failure Congress, Some COAPT Converts—and Some Pushback Shelley Wood May 30, 2019
News Daily News New European Hypertension Guidelines Not in Harmony With US Guidance Todd Neale June 11, 2018
News Daily News FDA’s Proposed Sodium Reduction Plan Could Have a Big Impact, Analysis Suggests Todd Neale April 11, 2018
News Industry News Novartis' new heart failure medicine LCZ696 approved by FDA to reduce risk of cardiovascular death and heart failure hospitalization; now called Entresto™ (sacubitril-valsartan) July 07, 2015